Trefoil Therapeutics

About Trefoil Therapeutics

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

What does Trefoil Therapeutics do?

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Where is Trefoil Therapeutics located?

Trefoil Therapeutics is based in San Diego, United States.

When was Trefoil Therapeutics founded?

Trefoil Therapeutics was founded in 2013.

How much funding has Trefoil Therapeutics raised?

Trefoil Therapeutics has raised $12.0M.

Location
San Diego, United States
Founded
2013
Funding
$12.0M
Employees
11 employees
Investors
Bios PartnersExsight VenturesSolasta Ventures

Trefoil Therapeutics

7
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

trefoiltherapeutics.com1K+
Founded 2013 – San Diego, United States

Funding

No specific funding rounds found.

Total Funding

$12.0M

Backed by

Bios PartnersExsight VenturesSolasta Ventures

Team (10+)

No team information available.

Company Description

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.